GAC - There is a lot of truth to the words you say. Investors generally look to what it could be after there is a life buoy thrown to them in the form of good news. Here are a couple of examples. Magna in 1990 had fallen from the mid $20's to just $2.05 a share just after Iraqu invaded Kuait. Management had ticked off many institutional investors who all ran for the exits. Frank S was removed and a couple of consultants were brought in to take control and turn the finances around. 2.5 yrs later they were $58 per share. JDS Uniphase, actually I can't remember the name on the Canadian side before the merger  but in 1993/94 they were scrambling to get financing to keep their doors open. In 97/98 they were able to announce that they were able to split the optic wave into its 7 primary colours of the light beam and get 7 times the volume of data passing through the single strand of fibre optic cable. The following year they announced they could split each of the individual colours in that beam into their individual colours and so on. In the end, around late 99 they were able to get 128 times the volume of traffic threw that single strand of fibre optic cable. That technology alone put 360 Networks out of business in short order. 

The point here is that both of these companies were living on the edge until some form of earth shaking news not only revived investors opinion them but shot them into the stratosphere. In the time frame above JDSU went from under $5 a share, split 4 times and peaked at just under $200 per share before the tech bubble burst in early 2000.

For RVX, because there is virtually no competition in the cognitive space, that market in the G8 countries is close to 3X's the diabetic CVD market and the CKD market is close to 6X's the diabetic CVD market plus the potential to used ABL in the future with non diabetic patients. Thinking about these possibilities gets me just a tad cranked up. 

If the results of BETonMACE meet the Door #1 criteria then I think it may be possible to see a JDSU type of action. Not to the same extent because we are starting from a much larger number of shares outstanding when this news hits but a much bigger number than most can even fathom just the same. Disappointing news from the BoM trial will not be nice to shareholders but that's the risk we are taking owning a development biotech that only spends money.

All IMO, dyodd.

tada